Literature DB >> 18202702

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4.

M Todaro1, Y Lombardo, M G Francipane, M Perez Alea, P Cammareri, F Iovino, A B Di Stefano, C Di Bernardo, A Agrusa, G Condorelli, H Walczak, G Stassi.   

Abstract

We investigated the mechanisms involved in the resistance to cell death observed in epithelial cancers. Here, we identify that primary epithelial cancer cells from colon, breast and lung carcinomas express high levels of the antiapoptotic proteins PED, cFLIP, Bcl-xL and Bcl-2. These cancer cells produced interleukin-4 (IL-4), which amplified the expression levels of these antiapoptotic proteins and prevented cell death induced upon exposure to TRAIL or other drug agents. IL-4 blockade resulted in a significant decrease in the growth rate of epithelial cancer cells and sensitized them, both in vitro and in vivo, to apoptosis induction by TRAIL and chemotherapy via downregulation of the antiapoptotic factors PED, cFLIP, Bcl-xL and Bcl-2. Furthermore, we provide evidence that exogenous IL-4 was able to upregulate the expression levels of these antiapoptotic proteins and potently stabilized the growth of normal epithelial cells rendering them apoptosis resistant. In conclusion, IL-4 acts as an autocrine survival factor in epithelial cells. Our results indicate that inhibition of IL-4/IL-4R signaling may serve as a novel treatment for epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202702     DOI: 10.1038/sj.cdd.4402305

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  84 in total

Review 1.  Leukocytes in mammary development and cancer.

Authors:  Lisa M Coussens; Jeffrey W Pollard
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

2.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

3.  Epithelial interleukin-4 receptor expression promotes colon tumor growth.

Authors:  Felicitas L Koller; Daniel G Hwang; E A Dozier; Barbara Fingleton
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

4.  Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.

Authors:  Julia S Pettersen; Judilyn Fuentes-Duculan; Mayte Suárez-Fariñas; Katherine C Pierson; Alexander Pitts-Kiefer; Linda Fan; Daniel A Belkin; Claire Q F Wang; Shivaprasad Bhuvanendran; Leanne M Johnson-Huang; Mark J Bluth; James G Krueger; Michelle A Lowes; John A Carucci
Journal:  J Invest Dermatol       Date:  2011-02-10       Impact factor: 8.551

Review 5.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

Review 6.  Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13.

Authors:  Miranda A Hallett; Katherine T Venmar; Barbara Fingleton
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

7.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.

Authors:  Vasilena Gocheva; Hao-Wei Wang; Bedrick B Gadea; Tanaya Shree; Karen E Hunter; Alfred L Garfall; Tara Berman; Johanna A Joyce
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

8.  IL-4 and IL-17A Cooperatively Promote Hydrogen Peroxide Production, Oxidative DNA Damage, and Upregulation of Dual Oxidase 2 in Human Colon and Pancreatic Cancer Cells.

Authors:  Yongzhong Wu; Mariam M Konaté; Jiamo Lu; Hala Makhlouf; Rodrigo Chuaqui; Smitha Antony; Jennifer L Meitzler; Michael J Difilippantonio; Han Liu; Agnes Juhasz; Guojian Jiang; Iris Dahan; Krishnendu Roy; James H Doroshow
Journal:  J Immunol       Date:  2019-09-23       Impact factor: 5.422

9.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Authors:  D Lecis; C Drago; L Manzoni; P Seneci; C Scolastico; E Mastrangelo; M Bolognesi; A Anichini; H Kashkar; H Walczak; D Delia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

10.  The mRNA expression of SATB1 and SATB2 in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Mansel; Robert Newbold; Kefah Mokbel
Journal:  Cancer Cell Int       Date:  2009-07-30       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.